Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Epstein-Barr Virus and the Pathogenesis of Diffuse Large B-Cell Lymphoma

AM. Ross, CI. Leahy, F. Neylon, J. Steigerova, P. Flodr, M. Navratilova, H. Urbankova, K. Vrzalikova, L. Mundo, S. Lazzi, L. Leoncini, M. Pugh, PG. Murray

. 2023 ; 13 (2) : . [pub] 20230214

Status not-indexed Language English Country Switzerland

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc23002926

Epstein-Barr virus (EBV), defined as a group I carcinogen by the World Health Organization (WHO), is present in the tumour cells of patients with different forms of B-cell lymphoma, including Burkitt lymphoma, Hodgkin lymphoma, post-transplant lymphoproliferative disorders, and, most recently, diffuse large B-cell lymphoma (DLBCL). Understanding how EBV contributes to the development of these different types of B-cell lymphoma has not only provided fundamental insights into the underlying mechanisms of viral oncogenesis, but has also highlighted potential new therapeutic opportunities. In this review, we describe the effects of EBV infection in normal B-cells and we address the germinal centre model of infection and how this can lead to lymphoma in some instances. We then explore the recent reclassification of EBV+ DLBCL as an established entity in the WHO fifth edition and ICC 2022 classifications, emphasising the unique nature of this entity. To that end, we also explore the unique genetic background of this entity and briefly discuss the potential role of the tumour microenvironment in lymphomagenesis and disease progression. Despite the recent progress in elucidating the mechanisms of this malignancy, much work remains to be done to improve patient stratification, treatment strategies, and outcomes.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23002926
003      
CZ-PrNML
005      
20230421100023.0
007      
ta
008      
230413s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/life13020521 $2 doi
035    __
$a (PubMed)36836878
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Ross, Aisling M $u Health Research Institute and School of Medicine, University of Limerick, V94 T9PX Limerick, Ireland $u BioScience and BioEngineering Research (BioSciBer), Bernal BioMaterials Cluster, Bernal Institute, University of Limerick, V94 T9PX Limerick, Ireland $1 https://orcid.org/0000000191393775
245    10
$a Epstein-Barr Virus and the Pathogenesis of Diffuse Large B-Cell Lymphoma / $c AM. Ross, CI. Leahy, F. Neylon, J. Steigerova, P. Flodr, M. Navratilova, H. Urbankova, K. Vrzalikova, L. Mundo, S. Lazzi, L. Leoncini, M. Pugh, PG. Murray
520    9_
$a Epstein-Barr virus (EBV), defined as a group I carcinogen by the World Health Organization (WHO), is present in the tumour cells of patients with different forms of B-cell lymphoma, including Burkitt lymphoma, Hodgkin lymphoma, post-transplant lymphoproliferative disorders, and, most recently, diffuse large B-cell lymphoma (DLBCL). Understanding how EBV contributes to the development of these different types of B-cell lymphoma has not only provided fundamental insights into the underlying mechanisms of viral oncogenesis, but has also highlighted potential new therapeutic opportunities. In this review, we describe the effects of EBV infection in normal B-cells and we address the germinal centre model of infection and how this can lead to lymphoma in some instances. We then explore the recent reclassification of EBV+ DLBCL as an established entity in the WHO fifth edition and ICC 2022 classifications, emphasising the unique nature of this entity. To that end, we also explore the unique genetic background of this entity and briefly discuss the potential role of the tumour microenvironment in lymphomagenesis and disease progression. Despite the recent progress in elucidating the mechanisms of this malignancy, much work remains to be done to improve patient stratification, treatment strategies, and outcomes.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Leahy, Ciara I $u Health Research Institute and School of Medicine, University of Limerick, V94 T9PX Limerick, Ireland $u BioScience and BioEngineering Research (BioSciBer), Bernal BioMaterials Cluster, Bernal Institute, University of Limerick, V94 T9PX Limerick, Ireland
700    1_
$a Neylon, Fiona $u Health Research Institute and School of Medicine, University of Limerick, V94 T9PX Limerick, Ireland $u BioScience and BioEngineering Research (BioSciBer), Bernal BioMaterials Cluster, Bernal Institute, University of Limerick, V94 T9PX Limerick, Ireland
700    1_
$a Steigerova, Jana $u Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olmouc, 775 15 Olomouc, Czech Republic
700    1_
$a Flodr, Patrik $u Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olmouc, 775 15 Olomouc, Czech Republic $u Department of Clinical and Molecular Pathology, University Hospital Olomouc, 779 00 Olomouc, Czech Republic
700    1_
$a Navratilova, Martina $u Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olmouc, 775 15 Olomouc, Czech Republic $u Department of Clinical and Molecular Pathology, University Hospital Olomouc, 779 00 Olomouc, Czech Republic
700    1_
$a Urbankova, Helena $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky Univesity and University Hospital Olomouc, 779 00 Olomouc, Czech Republic $1 https://orcid.org/0000000284992961 $7 xx0115681
700    1_
$a Vrzalikova, Katerina $u Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, UK
700    1_
$a Mundo, Lucia $u Health Research Institute and School of Medicine, University of Limerick, V94 T9PX Limerick, Ireland $u Department of Medical Biotechnologies, Section of Pathology, University of Siena, 53100 Siena, Italy
700    1_
$a Lazzi, Stefano $u Department of Medical Biotechnologies, Section of Pathology, University of Siena, 53100 Siena, Italy
700    1_
$a Leoncini, Lorenzo $u Department of Medical Biotechnologies, Section of Pathology, University of Siena, 53100 Siena, Italy
700    1_
$a Pugh, Matthew $u Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, UK $1 https://orcid.org/000000026324661X
700    1_
$a Murray, Paul G $u Health Research Institute and School of Medicine, University of Limerick, V94 T9PX Limerick, Ireland $u Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olmouc, 775 15 Olomouc, Czech Republic
773    0_
$w MED00186366 $t Life (Basel, Switzerland) $x 2075-1729 $g Roč. 13, č. 2 (2023)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36836878 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230413 $b ABA008
991    __
$a 20230421100015 $b ABA008
999    __
$a ok $b bmc $g 1922712 $s 1189133
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 13 $c 2 $e 20230214 $i 2075-1729 $m Life $n Life (Basel) $x MED00186366
LZP    __
$a Pubmed-20230413

Find record

Citation metrics

Archiving options